Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label Phase 1 safety and tolerability study of omadacycline and tigecycline in healthy adults.

Trial Profile

An open label Phase 1 safety and tolerability study of omadacycline and tigecycline in healthy adults.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 May 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omadacycline (Primary) ; Tigecycline
  • Indications Acute sinusitis; Anthrax; Community-acquired pneumonia; Nosocomial infections; Skin and soft tissue infections; Urinary tract infections
  • Focus Adverse reactions
  • Most Recent Events

    • 02 May 2017 New trial record
    • 25 Apr 2017 According to a Paratek Pharmaceuticals Media Release, data was presented at the annual meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2017)
    • 25 Apr 2017 Results published in a Paratek Pharmaceuticals Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top